A share price of Novavax, Inc [NVAX] is currently trading at $7.74, up 15.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NVAX shares have gain 22.08% over the last week, with a monthly amount glided 29.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novavax, Inc [NASDAQ: NVAX] stock has seen the most recent analyst activity on February 28, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $19. Previously, JP Morgan downgraded its rating to Underweight on July 30, 2024, and kept the price target unchanged to $8. On May 10, 2024, upgrade upgraded it’s rating to Neutral. BofA Securities upgraded its rating to a Neutral and increased its price target to $12 on May 10, 2024. B. Riley Securities upgraded its rating to a Buy but $15 remained the price target by the analyst firm on August 09, 2023. TD Cowen downgraded its rating to Market Perform for this stock on April 20, 2023, and downed its price target to $10. In a note dated March 01, 2023, B. Riley Securities downgraded an Neutral rating on this stock and revised its target price from $29 to $10.
Novavax, Inc experienced fluctuations in its stock price throughout the past year between $5.01 and $23.86. Currently, Wall Street analysts expect the stock to reach $50.8 within the next 12 months. Novavax, Inc [NASDAQ: NVAX] shares were valued at $7.74 at the most recent close of the market. An investor can expect a potential return of 556.33% based on the average NVAX price forecast.
Analyzing the NVAX fundamentals
Trailing Twelve Months sales for Novavax, Inc [NASDAQ:NVAX] were 1.25B which represents 610.30% growth. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.39%, and Net Profit Margin reading is 0.38%. To continue investigating profitability, this company’s Return on Assets is posted at 0.37, Equity is -1.16 and Total Capital is 0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Novavax, Inc [NASDAQ:NVAX] is 2.06. As well, the Quick Ratio is 2.03, while the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 1.00 and price to earnings (TTM) ratio is 2.92.
Transactions by insiders
Recent insider trading involved YOUNG JAMES F, Former Director, that happened on May 19 ’25 when 10000.0 shares were purchased. Former Director, YOUNG JAMES F completed a deal on Apr 14 ’25 to buy 4000.0 shares. Meanwhile, Director King Rachel K. sold 4150.0 shares on Dec 13 ’24.
